Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 23, 2022 - Issue 1
Submit an article Journal homepage
188
Views
3
CrossRef citations to date
0
Altmetric
Drug Evaluation

An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes

Brian Tomlinsona Faculty of Medicine, Macau University of Science and Technology, Macau, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3994-2030View further author information
ORCID Icon,
Paul Chanb Division of Cardiovascular Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei City, TaiwanORCID Iconhttps://orcid.org/0000-0003-4958-5487View further author information
ORCID Icon &
Christopher Wai Kei Lama Faculty of Medicine, Macau University of Science and Technology, Macau, ChinaORCID Iconhttps://orcid.org/0000-0001-6717-5444View further author information
ORCID Icon
Pages 29-42 | Received 09 Aug 2021, Accepted 22 Sep 2021, Published online: 11 Oct 2021

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Brian Tomlinson & Yan-Hong Li. (2023) Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date. Expert Opinion on Pharmacotherapy 0:0, pages 1-11.
Read now
Brian Tomlinson, Yan-Hong Li & Paul Chan. (2022) Evaluating gliclazide for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 23:17, pages 1869-1877.
Read now

Articles from other publishers (1)

Habib Ur Rehman, Attiq Ur Rehman Kakar, Mohammed Yaqoob, Muhammad Asghar, Syed Saeed Ahmed & Khair Un Nisa. (2022) Determination of pioglitazone hydrochloride by flow injection chemiluminescence tris(2,2 ′‐ bipyridyl)ruthenium(II)–silver(III) complex system . Luminescence 38:2, pages 99-108.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.